Stereotaxis to Present at 37th Annual Roth Conference
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced its participation in the 37th Annual ROTH Conference in Dana Point, California. Chairman and CEO David Fischel will be available for one-on-one meetings on March 17th, 2025.
The company's innovative technology has been utilized to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions. Stereotaxis specializes in developing robotic systems, instruments, and information solutions for the interventional laboratory, focusing on enhancing physician capabilities through robotic precision and safety, while expanding access to minimally invasive therapy and improving operating room productivity and connectivity.
Stereotaxis (NYSE: STXS), pioniere nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale ROTH a Dana Point, California. Il Presidente e CEO David Fischel sarà disponibile per incontri individuali il 17 marzo 2025.
La tecnologia innovativa dell'azienda è stata utilizzata per trattare oltre 150.000 pazienti in tutto il mondo, negli Stati Uniti, in Europa, Asia e altre regioni. Stereotaxis si specializza nello sviluppo di sistemi robotici, strumenti e soluzioni informative per il laboratorio interventistico, concentrandosi sul miglioramento delle capacità dei medici attraverso la precisione e la sicurezza robotica, ampliando l'accesso alla terapia minimamente invasiva e migliorando la produttività e la connettività in sala operatoria.
Stereotaxis (NYSE: STXS), pionero en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, anunció su participación en la 37ª Conferencia Anual ROTH en Dana Point, California. El presidente y CEO David Fischel estará disponible para reuniones individuales el 17 de marzo de 2025.
La tecnología innovadora de la empresa ha sido utilizada para tratar a más de 150,000 pacientes en todo el mundo, incluyendo Estados Unidos, Europa, Asia y otras regiones. Stereotaxis se especializa en el desarrollo de sistemas robóticos, instrumentos y soluciones informáticas para el laboratorio de intervención, enfocándose en mejorar las capacidades de los médicos a través de la precisión y la seguridad robótica, mientras amplía el acceso a la terapia mínimamente invasiva y mejora la productividad y conectividad en el quirófano.
스테레오택시스 (NYSE: STXS), 최소 침습 혈관 내 수술을 위한 외과 로봇의 선두주자로, 캘리포니아 다나 포인트에서 열리는 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다. 회장 겸 CEO인 데이비드 피셸은 2025년 3월 17일에 일대일 미팅을 위해 자리를 마련할 예정입니다.
회사의 혁신적인 기술은 미국, 유럽, 아시아 및 기타 지역에서 전 세계적으로 150,000명 이상의 환자를 치료하는 데 사용되었습니다. 스테레오택시스는 중재 실험실을 위한 로봇 시스템, 기구 및 정보 솔루션을 개발하는 데 전문화되어 있으며, 로봇의 정밀성과 안전성을 통해 의사의 능력을 향상시키고 최소 침습 치료 접근성을 확대하며 수술실의 생산성과 연결성을 개선하는 데 중점을 두고 있습니다.
Stereotaxis (NYSE: STXS), un pionnier de la robotique chirurgicale pour les interventions endovasculaires peu invasives, a annoncé sa participation à la 37e Conférence Annuelle ROTH à Dana Point, Californie. Le président et PDG David Fischel sera disponible pour des réunions individuelles le 17 mars 2025.
La technologie innovante de l'entreprise a été utilisée pour traiter plus de 150 000 patients dans le monde entier, notamment aux États-Unis, en Europe, en Asie et dans d'autres régions. Stereotaxis se spécialise dans le développement de systèmes robotiques, d'instruments et de solutions d'information pour le laboratoire d'intervention, en se concentrant sur l'amélioration des capacités des médecins grâce à la précision et à la sécurité robotiques, tout en élargissant l'accès aux thérapies peu invasives et en améliorant la productivité et la connectivité en salle d'opération.
Stereotaxis (NYSE: STXS), ein Pionier in der chirurgischen Robotik für minimalinvasive endovaskuläre Eingriffe, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz in Dana Point, Kalifornien, bekannt gegeben. Der Vorsitzende und CEO David Fischel wird am 17. März 2025 für persönliche Gespräche zur Verfügung stehen.
Die innovative Technologie des Unternehmens wurde weltweit zur Behandlung von über 150.000 Patienten in den USA, Europa, Asien und anderen Regionen eingesetzt. Stereotaxis ist auf die Entwicklung von robotergestützten Systemen, Instrumenten und Informationslösungen für das interventionelle Labor spezialisiert und konzentriert sich darauf, die Fähigkeiten der Ärzte durch robotische Präzision und Sicherheit zu verbessern, den Zugang zu minimalinvasiven Therapien zu erweitern und die Produktivität und Konnektivität im Operationssaal zu steigern.
- None.
- None.
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th Annual ROTH Conference in Dana Point, California.
Mr. Fischel will be available for one-on-one meetings on Monday, March 17th, 2025.
“We appreciate the opportunity to participate in the Roth Conference and to share Stereotaxis’ differentiated technology and growth strategy with the investment community,” says Mr. Fischel.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When is Stereotaxis (STXS) presenting at the ROTH Conference 2025?
How many patients have been treated using Stereotaxis (STXS) technology?
What is the main focus of Stereotaxis (STXS) surgical robotics technology?
Where is Stereotaxis (STXS) technology currently being used?
What are the key benefits of Stereotaxis (STXS) robotic systems?
